Ruxolitinib Versus Anagrelide in Patients Resistant or Intolerant to Hydroxyurea
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Ruxolitinib Versus Anagrelide in Patients Resistant or Intolerant to Hydroxyurea

Sponsor: Incyte Corporation

A phase 2 study of ruxolitinib versus anagrelide in patients diagnosed with essential thrombocythemia that are resistant to or intolerant of hydroxyurea and who have not previously undergone treatment with either ruxolitinib or anagrelide.